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Phase IIa b s t r a c t
We designed a placebo controlled, double-blind, randomized, dose-finding phase II study on OMT-28 in
the maintenance of sinus rhythm after electrical cardioversion (DCC) in patients with persistent atrial fib-
rillation (PROMISE-AF). OMT-28 is a first-in-class, synthetic analog of 17,18-epoxyeicosatetetraenoic
acid, a bioactive lipid mediator generated by cytochrome P450 enzymes from the omega-3 fatty acid
eicosapentaenoic acid. OMT-28 improves Ca2+-handling and mitochondrial function in cardiomyocytes
and reduces pro-inflammatory signaling. This unique mode of action may provide a novel approach to
target key mechanism contributing to AF pathophysiology. In a recent phase I study, OMT-28 was safe
and well tolerated and showed favorable pharmacokinetics. The PROMISE-AF study (NCT03906799) is
designed to assess the efficacy (primary objective), safety, and population pharmacokinetics (secondary
objectives) of three different doses of OMT-28, administered once daily, versus placebo until the end of
the follow-up period. Recruitment started in March 2019 and the study will include a total of 120
patients. The primary efficacy endpoint is the AF burden (% time with any AF), evaluated over a 13-
week treatment period after DCC. AF burden is calculated based on continuous ECG monitoring using
an insertable cardiac monitor (ICM). The primary efficacy analysis will be conducted on the modified
intention-to-treat (mITT) population, whereas the safety analysis will be done on the safety population.
Although ICMs have been used in other interventional studies to assess arrhythmia, PROMISE-AF will be
the first study to assess antiarrhythmic efficacy and safety of a novel rhythm-stabilizing drug after DCC
by using ICMs.
 2020 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Atrial fibrillation (AF) is the most common cardiac arrhythmia
affecting worldwide more than 30 million patients [1,2]. AF is asso-
ciated with an increased risk for stroke, heart failure and dementia,
increased morbidity and mortality in affected patients and causes
significant health costs [1,2].
AF is a clinical condition which may progress from paroxysmal
(duration < 7 days, self-terminating), to persistent
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and permanent AF (despite treatment no restoration of normal
sinus rhythm or not treated) [3]. The pathogenesis is multifactorial
and includes risk factors like coronary artery disease, valvular
heart disease, hypertension, heart failure, diabetes, sleep apnea,
obesity, inflammation, and activation of the autonomic nervous
system [4].
Manifestation of electrical (e.g., ion channel dysfunction, con-
duction slowing) and structural (e.g., interstitial fibrosis, cellular
hypertrophy, mitochondrial dysfunction) remodeling are key ele-
ments of the substrate that promotes the progression of AF to more
persistent forms and contributes to the development of an atrial
cardiomyopathy that supports the persistence of AF [5–9].
1.1. Standard of care and unmet medical need for novel therapies
Current AF treatment comprises prevention of thromboem-
bolism and stroke, risk factor management as well as antiarrhyth-
mic therapy by drugs, electrical cardioversion, and catheter
ablation [10]. Effective long-term rhythm control improves quality
of life and can reduce associated health risk factors. Despite recent
advances in interventional ablation therapy [11], antiarrhythmic
drugs (AADs) remain the cornerstone treatment option for the
majority of AF patients worldwide, although AADs are only moder-
ately effective and possess substantial cardiac and non-cardiac tox-
icity. Thus, there is an unmet need for novel AADs with improved
efficacy and safety profiles [12]. The expected increase in AF preva-
lence with the aging of the population increases the pressure to
develop improved AADs because invasive ablation procedures can-
not be applied to this large patient population. In addition, the
improvement of AF detection methods, e.g., the use of (insertable)
cardiac monitors (ICMs) for continuous 24/7 surveillance of
patients or emerging wearable, home-based AF sensors [13],
enhances continuously the understanding of the disease and calls
for improvement of AADs available. Compared to the electrocardio-
gram (ECG)-based assessment of the AF phenotypes, continuous
and long-term AF monitoring offers improved opportunities to
define and quantify the real AF burden, the relationship of AF bur-
den to cardiovascular and neurological outcomes, and the success
rate of AF treatments [14,15].
Currently marketed AADs follow the classic concepts of selec-
tive channel and multichannel block. However, low long-term effi-
cacy and the risk of proarrhythmia along with non-cardiac adverse
events are relevant disadvantages limiting the clinical benefit for
AF patients [16–18]. Conceptually, novel AADs should target the
multifactorial pathogenesis of AF and ideally prevent the develop-
ment and halt the progression of the AF-promoting atrial
cardiomyopathy. Several molecular mechanisms contributing to
AF-promoting electrical and structural remodeling have been
identified as potential molecular targets for novel therapeutic
approaches [19] including alterations in intracellular Ca2+-
handling [9,20,21], mitochondrial dysfunction [22], oxidative
stress [23], and inflammatory signaling [24,25]. A new paradigm
in the pharmacotherapy treatment of AF should consider the
patients’ individual arrhythmia mechanism and co-morbidities
with the aim to increase both therapeutic efficacy and safety [26].
1.2. OMT-28 to reinforce endogenous mechanisms of cardioprotection
and antiarrhythmia
OMT-28 is a metabolically robust synthetic analog of 17,18-
epoxyeicosatetraenoic acid (17,18-EEQ) and has been developed
to mimic the antiarrhythmic and cardioprotective mechanisms of
endogenous omega-3 epoxyeicosanoids [27]. Omega-3 epoxye-
icosanoids are bioactive lipid mediators generated by cytochrome
P450 (CYP) enzymes from long-chain omega-3 polyunsaturatedfatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA). 17,18-EEQ is the main product of
EPA metabolism as catalyzed by CYP2J2, the major CYP epoxyge-
nase in the human heart [28]. Upon dietary EPA/DHA supplemen-
tation, 17,18-EEQ is the predominant epoxyeicosanoid both in
rodents [28] and humans [29].
Omega-3 epoxyeicosanoids protect cardiomyocytes against
Ca2+ overload [28], inflammatory injury [30], and hypoxia/
reoxygenation-induced loss of cell viability and mitochondrial
function [31]. Most recently, the cardioprotective effect of
omega-3 epoxyeicosanoids was shown to involve inhibition of
inflammatory signaling [32]. There is also evidence from animal
studies indicating that reinforcing the CYP epoxygenase pathway
has the potential to protect against cardiac remodeling and
arrhythmia [33,34]. In line with this notion, transgenic overexpres-
sion of CYP2J2 [35], as well as inhibition of soluble epoxide
hydrolase-mediated epoxyeicosanoid degradation [36], was shown
to reduce ventricular tachyarrhythmia and AF vulnerability in
mice.
OMT-28 shares the cardioprotective and antiarrhythmic prop-
erties with its natural counterparts. Omega-3 epoxyeicosanoids
and OMT-28 act via a putative Gai protein-coupled receptor, which
elicits PI3K/Akt/eNOS/PKG signaling as well as activation of sirtuin-
1 and PPARa in cardiomyocytes. The net effect of this pathway con-
sists in modulation of Ca2+-cycling, reduced electrical excitability,
and protection against mitochondrial dysfunction and inflamma-
tory injury (Fig. 1). This multimodal mode of action differentiates
OMT-28 from the classical ion channel-inhibiting AADs and has
the potential to simultaneously target several of the key mecha-
nisms contributing to the evolution of the AF-promoting atrial sub-
strate and an arrhythmia-related cardiomyopathy of the ventricles.1.3. OMT-28 – results of the phase I study
OMT-28 was developed as an orally active compound. In an
already completed phase I study in 76 healthy volunteers
(NCT03078738), OMT-28 was proven to be safe and well tolerated
in single and multiple ascending oral doses up to 60 mg once daily
for up to 14 days. OMT-28 had no detectable effect on the normal
values of investigated safety laboratory parameters, as well as
heart rate and blood pressure. Notably, high-resolution ECGs
excluded any exposure-related increase in the QTc interval. The
compound reached steady-state within 14 days of once-daily dos-
ing and showed high oral bioavailability and favorable pharma-
cokinetics with a fast uptake into the plasma (tmax of 1.25–2.0 h,
median) and a plasma half-life (t1/2) of 65.8–85.9 h (median), val-
idating its suitability for oral, once daily application.2. Methods
2.1. PROMISE-AF study design [ClinicalTrials.gov Identifier:
NCT03906799]
We designed a placebo-controlled, double-blind, randomized,
dose-finding, multicenter phase II study in patients with persistent
AF for > 7 days but  3 months who are suitable for direct current
cardioversion (DCC) (Fig. 2). This study evaluates the efficacy,
safety, and population pharmacokinetic (popPK) of three different
doses of OMT-28 given once daily versus placebo in patients with
persistent AF in maintaining sinus rhythm after DCC.
This study will be conducted in compliance with the protocol,
the ethical principles as outlined in the Declaration of Helsinki,
the International Conference on Harmonization (ICH) consolidated
Guideline E6 for Good Clinical Practice (CPMP/ICH/135/95), and
applicable regulatory requirement(s).
Abbreviations: Akt - protein kinase B (PKB), ATP - adenosine triphosphate, GPCR - G protein-
coupled receptors, LTCC - L-type calcium channel, NCX1 - sodium-calcium exchanger type 1, NFκB 
- nuclear factor kappa-light-chain-enhancer of activated B cells, PI3K - phosphoinositide 3-kinase, 
PKG - protein kinase G/cGMP-dependent protein kinase, PPARα - peroxisome proliferator-activated 
receptor alpha, RyR2 - ryanodine receptor channel type 2, SERCA2a - sarcoplasmic/endoplasmic 
reticulum calcium ATPase type 2a, SIRT1 - sirtuin-1. 
Fig. 1. Putative mechanisms of antiarrhythmic actions of OMT-28.
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This study will enroll patients with documented AF for > 7 days
but 3 months that are eligible for DCC and anticoagulant therapy.
Patients with prior or ongoing anticoagulant and/or single antipla-
telet therapy are eligible as well as treatment-naïve patients. In
contrast, patients with dual antiplatelet therapy are excluded
because therapy also in combination with anticoagulants (i.e., tri-
ple therapy) is known to be associated with an increased risk of
bleeding [37–40]. Patients that have undergone surgical or cathe-
ter ablation for AF or atrial flutter are not allowed to participate
in the study. However, patients with medical history of atrial flut-
ter were not excluded because it is a common finding in AF
patients and recruitment was not to be jeopardized. Nonetheless,
special attention will be paid to these patients, i.e., information
on incidence and duration of atrial flutter will be recorded as
exploratory endpoint. Detailed inclusion and exclusion criteria
are shown in Supplemental Table 1.2.1.2. Study medication
OMT-28 will be administered orally in form of microcrystalline
cellulose and anhydrous silica containing capsules of three differ-
ent strengths. OMT-28 will be tested against placebo in patients
receiving standard of care therapy, including anticoagulant or rate
control therapy (e.g., Ca2+-channel blocker, b-blocker). Patients
taking antiarrhythmic agents including dronedarone, oral amio-
darone, or omega-3 fatty acids will not be included – exclusion cri-
teria 15 and 16. If during the study, the use of above-mentionedagents is deemed necessary by the investigator, the patient must
be withdrawn from the study. The first dose of study drug is
administered during Visit 3 under the supervision of the investiga-
tor. The study drug is labelled according to the ICH-GCP Guideline
E6 (European Commission2/3/2010).
2.1.3. Study objectives & endpoints
The primary objective of the study is to assess the efficacy of
three different doses of OMT-28 administered once daily versus
placebo in the maintenance of normal sinus rhythm after electrical
DCC in patients with persistent AF treated with an appropriate
anticoagulant therapy.
The secondary objective of the study is the assessment of (i) the
safety of three different doses of OMT-28 administered once daily
versus placebo after DCC in patients with persistent AF and (ii) the
PK of OMT-28 by means of popPK analysis.
All primary, secondary, and exploratory study endpoints on effi-
cacy (incl. biomarker analysis) and safety are summarized in
Table 1.
2.1.3.1. Key measurement – insertable cardiac monitor. All patients
will undergo ICM insertion during randomization at Visit 2. The
trigger of the ICM from BIOTRONIK, BioMonitor 2-AF, will be pro-
grammed to detect the following arrhythmic events: AF, asystole,
bradycardia, and high ventricular rate. The confirmation time for
an AF episode is set from 6 min (standard settings) to 2 min.
Further details on the study-specific programming are listed in
Supplemental Table 2. Furthermore, patients will be equipped with
Fig. 2. Phase II study design and flowchart.
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trigger ICM recording in case of any symptoms.
Data recorded by the ICM will be transferred into the BIOTRO-
NIK HomeMonitoring Service Center and finally into the software
inSuite Cardio (Doc Cirrus), the latter allowing transfer of the data
to the independent ICM Data Review Committee (ICM-DRC), com-
prising of qualified cardiologists who are not investigators in the
study and not otherwise directly associated with the study spon-
sor, responsible for the evaluation of recorded episodes. The mem-
bers of the committee will remain blinded to treatment throughout
the evaluation process and the study. Evaluated data will be used
in the final efficacy and safety analyses.2.1.3.2. Pharmacokinetics. A popPK analysis will be performed to
gain relevant PK information in patients who are representative
of the target population. There will be two study visits – at the
beginning of treatment and at steady state (Visit 3, Day 1 and Visit
6, Day 43 ± 3) – with one pre-dose and three post-dose blood sam-
pling procedures (within 15–45 min post dose, 1–2 h post dose,
and 2.5–8 h post-dose). At Visit 4, 5, 7, 8, and 9 there will be one
pre-dose sample only.2.1.3.3. Pharmacodynamics. Blood samples for PD assessment will
be taken pre-dose at Visit 3, Day 1 and at steady state at Visit 8,Day 99. PD biomarker analysis includes the analysis of different
cytokines, fatty acid profile in erythrocytes, or the endogenous
CYP eicosanoid profile. Further PD analysis will be performed on
proteins that are biologically related to (i) persistent AF and its
progression and (ii) the known mode of action of OMT-28 and
are, therefore, likely involved in further pharmacological effects.
This includes biomarkers of oxidative stress, inflammation, and
remodeling like growth differentiation factor 15 (GDF15),
Interleukin-6 (IL-6), transforming growth factor beta-1 (TGF-b1),
N-terminal pro-A/B-type natriuretic peptide (NT-proANP/NT-
proBNP), tissue inhibitors of metalloproteinases metallopeptidase
inhibitor 1 (TIMP-1), matrix metallopeptidase 9 (MMP-9),
Galectin-3, glycated hemoglobin (HbA1c), and high-sensitivity tro-
ponin I. Measurement of C-reactive protein (CRP), total cholesterol,
triglycerides, low density lipoprotein (LDL), high-density lipopro-
tein (HDL) and very low-density lipoprotein (VLDL) will allow to
assess OMT-28-related changes in inflammation and lipid
metabolism.2.1.4. Study visit schedule
2.1.4.1. Overview. Patients will be screened for eligibility during the
screening period (within 22 days prior to dosing) (Fig. 2). At latest
at randomization (Visit 2), the duration of the current episode of
Table 1
Primary, secondary, and exploratory efficacy and safety endpoints.
Study Endpoints
Primary Efficacy Endpoint
 AF burden (% time with any AF after direct current cardioversion, DCC). This is defined as the area under the curve for daily estimates (Day 8-Day 99). In case of
repeated DCC, the burden for the day of DCC and all following days will be estimated as the median of burden from onset of the current AF episode until DCC.
Secondary Efficacy Endpoints
 Recurrence rate (RecR) of persistent AF (defined as AF burden  23/24 h over 7 consecutive days) in at least one 7-day period
 Time-to-recurrence (TTR) defined as days from the successful cardioversion to first documented recurrence (TTR) of persistent AF (defined as AF burden  23/24 h
over 7 consecutive days) in at least one 7-day period
Exploratory Efficacy Endpoints
 RecR of non-persistent AF (defined as at least one AF episode not fulfilling the persistent AF definition)
 TTR of non-persistent AF (defined as at least one AF episode not fulfilling the persistent AF definition)
 AF burden during the first week of study drug intake prior to cardioversion
 AF burden during the first week of study drug intake prior to cardioversion compared to baseline
 AF burden after DCC compared to baseline
 Incidence of conversion to sinus rhythm during the first week of study drug intake prior to cardioversion
 Incidence of DCC procedures after successful DCC on Visit 4
 Incidence and duration of atrial flutter/atrial tachycardia
 Data collected from the patient diaries
Safety Endpoints
 Incidence, severity, seriousness, and treatment-causality of AEs
 Clinically significant changes in safety laboratory evaluations, vital signs, 12 lead ECGs, ICM data, and physical examinations
Pharmacokinetic and Exploratory Pharmacodynamic Endpoints
 Pharmacokinetic (evaluated by means of popPK analysis)
o Plasma concentration of OMT-28 and metabolites
o Trough plasma concentration (Ctrough)
 Pharmacodynamic biomarker at baseline (Visit 3, Day 1) and at steady state (Visit 8, Day 99)
o Serum biomarkers (GDF-15, Galectin-3, NT-proANP, NT-proBNP)
o Metabolic biomarker (HbA1c, serum lipids)
S. Berlin et al. / IJC Heart & Vasculature 29 (2020) 100573 5persistent AF must be shown to be > 7 days but  3 months, as con-
firmed by two ECGs (one ECG must be a 12-lead ECG).
Patients will be randomized, stratified by sex in order to avoid
gender-related exposure differences, in a 1:1:1:1-ratio to receive
once-daily OMT-28 at a dose of 4, 12, or 24 mg or placebo. The fol-
lowing controls will be employed to maintain the double-blind sta-
tus of the study: (i) placebo capsules will be identical in
appearance to the OMT-28 capsules, (ii) investigator(s) and other
members of staff involved with the study will remain blinded to
the treatment randomization code during the assembly procedure,
and (iii) all data will be provided to the Contract Research Organi-
zation in a blinded manner. Therefore, an Interactive Web
Response System (IWRS) is implemented in the study and study
medication bottles will be delivered automatically in a blinded
fashion. Whenever necessary, in the opinion of the investigator,
the study blind may be broken, and the patient will be withdrawn
from the study. Date, time, and reason of the decision will be
recorded in the patient’s source data.
At the same visit, Visit 2, patients will receive the ICM device,
which will be inserted subcutaneously under local anesthesia
according to local treatment guidelines.
Eligible patients with proven persistent AF must have received
adequate anticoagulant therapy for at least three weeks prior to
first administration of study drug (OMT-28 or placebo) on Visit 3.
Patients will receive study drug for at least one week prior to
DCC on Visit 4.
In total, each patient will be treated over a period of 99 days
once daily with either placebo or one of three doses of OMT-28.
The definition for the treatment duration goes back to an extensive
literature research, which showed that the timepoint of ~13 weeks
is, for most AF post-DCC trials, predictive for the 6 months out-
come. A comparable study (incl. placebo-control and post-DCC
treatment) from De Ferrari et al. had only a slightly longer treat-
ment duration of 16 weeks [41]. The treatment phase is followed
by an observation/follow-up phase of further 28 days (Fig. 2). No
long-term follow-up is planned; however the patients are allowed
to keep the ICM inserted.Patients will be monitored for cardiac events throughout the
study (Visit 2 to Visit 9) using the ICM. In addition, patients are
requested to complete daily a patient diary to report subjectively
perceived symptoms.
The study will include a sample size re-estimation analysis,
when approximately 50% of the patients have completed the treat-
ment phase (Visit 8).
2.1.4.2. DCC. On Visit 4 (seven days after start of study drug admin-
istration), provided that anticoagulation is adequate in the preced-
ing four weeks, patients remaining in AF, as confirmed by 12-lead
ECG, will undergo DCC (performed according to the current local
institutional practices). Patients will be allowed to receive more
than one direct current shock if the first attempt failed to restore
sinus rhythm. A 12-lead ECG will be performed 2 h after the
DCC. Only patients with a successful cardioversion (i.e., who
remain in sinus rhythm for at least 2 h after the DCC) will be
included in the mITT population.
All patients (including those who do not remain in sinus rhythm
for at least 2 h after the DCC) will continue to receive study drug
and continue to be monitored throughout the remainder of the
study. Patients who were not successfully cardioverted may be
replaced.
2.1.5. Sample size calculation
The study aims to demonstrate that OMT-28 compared to pla-
cebo improves at least one of the three efficacy endpoints – AF bur-
den, recurrence rate (RecR), and time-to-recurrence (TTR) – in the
3-months treatment period (Day 8-Day 99). AF burden is defined
as % time with any AF after DCC. According to the set triggers all
AF episodes > 2 min duration are considered. RecR refers to persis-
tent AF (defined as AF burden  23/24 h over 7 consecutive days)
in at least one 7-day period. TTR is defined as the time (days) from
the successful cardioversion to first documented recurrence of per-
sistent AF in at least one 7-day period. Therapeutic effects of OMT-
28 on RecR and/or TTR will be reflected in AF burden and no formal
sample size estimation has been done for these measures. The
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power) – reflected in changes of AF burden – is set to 80%. The
probability of a false positive finding (significance level) is set to
5%. Statistical tests will be done with a predefined direction of dif-
ference, thus one-tailed significance level will be computed. An
interim analysis will be performed if 50% of patients completed
treatment phase (Visit 8). As such preliminary analysis increases
the chance for false positive findings, the p-value will be adjusted
for multiple testing. The O’Brien Fleming methodology of splitting
alpha will be used. P-threshold for the interim analyses will be
0.005574597, leading to a remaining p-threshold of 0.044425403
for the final analysis.
The estimated sample size is the number of patients per treat-
ment group in the mITT population, as this is the primary popula-
tion for evaluation of efficacy. Since published AF burden data in a
post-DCC population from an interventional study with compara-
ble design was not available, sample size was estimated based on
simulations with parameters set according to published results
[42]. As base population, a random sample from a beta-
distribution with shape parameters of 0.55 and 1 was drawn with
100,000 patients. From these data, a sub-population was filtered
with AF burden between 2% and 95%. This population reflects the
expected baseline values in the study population. From this popu-
lation, 1000 samples per sample size were drawn and tested for
significance. The RecR of placebo was set to 50, 60, 70, 80, or
85%. The effect size of verum compared to placebo (DRecR) was
set - for each individual RecR placebo setting separately - to
±0, 5, 10, 20, and 30% to reflect a broad range of scenarios
(e.g., RecR placebo 70%: RecR verum 70, 65, 60, 50, and 40%). As
most realistic scenario, the RecR for placebo was set to 50%; the
RecR for all treatment groups (verum) was set to 30%. Reduction
in AF burden is the expected mean reduction of AF burden in
patients with recurring AF. Atrial fibrillation burden reduction
was set to 60%. This is a conservative estimate for the reduction
of AF burden in the study as the ‘‘000 for non-recurring AF will be
included in the computation from study data. 1000 samples were
simulated with affected/unaffected subjects according to RecR for
placebo/verum and affected subjects with 60% reduced burden in
simulated AF burden for verum only. For each simulation run, pla-
cebo vs. verumwere compared by non-parametric tests, the rate of
significant results over all simulations determined empirical
power. Under these assumptions, 30 patients per study arm will
give the desired statistical power. An interim analysis for sample
size re-estimation will be performed once approximately 15
patients per study arm have completed the treatment phase (Visit
8) of the study to avoid an underpowered study because of impre-
cise estimates for study population or overoptimistic parameter
estimates.
2.1.6. Study conduct & organization
2.1.6.1. Study conduct. For the purpose of study conduct, 25 study
sites in 4 different countries (Bulgaria, Czech Republic, Hungary,
and Ukraine) were initiated. The recruitment of the study started
in March 2019 and is expected to be completed within 9 months.
2.1.6.2. Study organization. All investigators, sub-investigators,
study coordinators and other involved site staff are obliged to com-
ply with the study specifications.
An independent Data Monitoring Committee (DMC) is responsi-
ble for ensuring the safety and well-being of study patients, study
integrity, and validity of study results by reviewing safety and effi-
cacy data. Based on ongoing study data, the DMC is expected to
make recommendations concerning study continuation, modifica-
tion, and termination, if needed.
A quality control was implemented by installation of the inde-
pendent, study-specific ICM-DRC, which will review recorded ECGs(6 per day per patient) in a blinded way and comment on the
recorded episodes (true/false/not evaluable). Evaluated data will
be considered for the final efficacy and safety analyses.
The study is funded by OMEICOS Therapeutics GmbH. The
authors are solely responsible for the design and conduct of the
study as well as drafting and editing of the manuscript, and its final
contents.
3. Conclusions
In summary, PROMISE-AF is a clinical phase II a/b dose-finding
study evaluating three doses of OMT-28 compared to placebo in
patients undergoing planned electrical cardioversion for persistent
AF. The use of an ICM in all patients will allow to calculate the AF
burden and other standard AF efficacy endpoints based on contin-
uous monitoring and thus provide an extensive data set for the
analysis and interpretation of the study results as a guidance for
further clinical development of OMT-28.
Any Potential Conflicts of Interest, Including Related Consul-
tancies, Shareholdings and Funding Grants
Sarah Berlin, Luciana Summo, Janine Lossie, Alexander Gebauer,
and Robert Fischer are employees of OMEICOS Therapeutics. Wolf
Schunck is Board Director of OMEICOS Therapeutics. Andreas
Goette has served as a consultant and speaker for Bayer Health
Care, MSD, Sanofi Aventis, BMS/Pfizer, Daiichi Sankyo, Boehringer
Ingelheim and OMEICOS Therapeutics. Dobromir Dobrev is mem-
ber of Scientific Advisory Boards of OMEICOS Therapeutics, Acesion
Pharma and Sanofi and received speaker’s fees for educational lec-
tures from Boston Scientific, Novartis and Bristol-Myers Squibb.
His laboratory executed research contracts for OMEICOS Therapeu-
tics. Gerald V. Naccarelli has received the following (outside the
submitted work): personal fees from Acesion, Correvio, Janssen,
Milestone, OMEICOS Therapeutics, and Sanofi; grants from Janssen.
Naab Al-Saady is an employee of Covance Inc. (study contract
research organization). John Camm has received personal fees form
Correvio, Sanofi, Acesion Pharma, OMEICOS Therapeutics, Huya,
Milestone, and Incarda.
CRediT authorship contribution statement
Sarah Berlin: Writing - original draft, Visualization, Project
administration. Andreas Goette: Writing - review & editing, Con-
ceptualization, Methodology. Luciana Summo: Writing - review
& editing, Project administration. Janine Lossie: Writing - review
& editing. Alexander Gebauer: Writing - review & editing, Project
administration, Supervision, Funding acquisition, Conceptualiza-
tion, Methodology. Naab Al-Saady: Writing - review & editing.
Leonardo Calo: Writing - review & editing, Conceptualization,
Methodology. Gerald Naccarelli: Writing - review & editing, Con-
ceptualization, Methodology. Wolf-Hagen Schunck: Writing -
original draft, Visualization, Conceptualization, Methodology.
Robert Fischer: Writing - original draft, Visualization, Funding
acquisition, Conceptualization, Methodology. A. John Camm:Writ-
ing - review & editing, Conceptualization, Methodology. Dobromir
Dobrev: Writing - review & editing, Conceptualization,
Methodology.
Acknowledgment
We acknowledge the contributions and continuous support by.
 The Clinical Advisory Board Members of OMEICOS Therapeutics
GmbH: L. Caló, MD, University Cattolica, Rome (Italy); A.J.
Camm, MD, FRCP, University of London and Imperial College
(United Kingdom); D. Dobrev, MD, FIACS, FISHR, University of
S. Berlin et al. / IJC Heart & Vasculature 29 (2020) 100573 7Duisburg-Essen (Germany); A. Goette, MD, FEHRA, St. Vincenz-
Hospital, Paderborn (Germany); G. Naccarelli, MD, FACC, FAHA,
FHRS, Pennsylvania State University, Pennsylvania (USA).
 The Members of the Data Monitoring Committee (DMC): U.
Tebbe, MD, B. Katgely, MD, and M. Klasser.
 The Members of the Insertable Cardiac Monitor Data Review
Committee (ICM-DRC): F. Günther, MD, A. Ohler, MD, and W.
Haverkamp, MD, from ExCard GmbH, Berlin (Germany).
We would also like to thank A. Busjahn (HealthTwist GmbH) for
his support in sample size planning, R. Sroka (Semdatex GmbH)
and D. Haverkamp (ExCard GmbH) in data management.Appendix A. Supplementary material
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.ijcha.2020.100573.References
[1] S.S. Chugh, R. Havmoeller, K. Narayanan, D. Singh, M. Rienstra, E.J. Benjamin,
et al., Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease
2010 Study, Circulation 129 (8) (2014) 837–847.
[2] R.B. Schnabel, X. Yin, P. Gona, M.G. Larson, A.S. Beiser, D.D. McManus, et al., 50
year trends in atrial fibrillation prevalence, incidence, risk factors, and
mortality in the Framingham Heart Study: a cohort study, Lancet 386 (9989)
(2015) 154–162.
[3] V. Fuster, L.E. Rydén, D.S. Cannom, H.J. Crijns, A.B. Curtis, K.A. Ellenbogen, et al.,
ACC/AHA/ESC 2006 guidelines for the management of patients with atrial
fibrillation, Circulation 114 (2006) e257–e354.
[4] D.H. Lau, S. Nattel, J.M. Kalman, P. Sanders, Modifiable risk factors and atrial
fibrillation, Circulation 136 (6) (2017) 583–596.
[5] J. Andrade, P. Khairy, D. Dobrev, S. Nattel, The clinical profile and
pathophysiology of atrial fibrillation: relationships among clinical features,
epidemiology, and mechanisms, Circ. Res. 114 (9) (2014) 1453–1468.
[6] A. Goette, J.M. Kalman, L. Aguinaga, J. Akar, J.A. Cabrera, S.A. Chen, et al., EHRA/
HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition,
characterization, and clinical implication, Heart Rhythm 14 (1) (2017) e3–e40.
[7] L. Schild, A. Bukowska, A. Gardemann, P. Polczyk, G. Keilhoff, M. Tager, et al.,
Rapid pacing of embryoid bodies impairs mitochondrial ATP synthesis by a
calcium-dependent mechanism - a model of in vitro differentiated
cardiomyocytes to study molecular effects of tachycardia, BBA 1762 (6)
(2006) 608–615.
[8] A. Bukowska, L. Schild, G. Keilhoff, D. Hirte, M. Neumann, A. Gardemann, et al.,
Mitochondrial dysfunction and redox signaling in atrial tachyarrhythmia, Exp.
Biol. Med. (Maywood) 233 (5) (2008) 558–574.
[9] J. Heijman, N. Voigt, S. Nattel, D. Dobrev, Cellular and molecular
electrophysiology of atrial fibrillation initiation, maintenance, and
progression, Circ. Res. 114 (9) (2014) 1483–1499.
[10] C.T. January, L.S. Wann, H. Calkins, L.Y. Chen, J.E. Cigarroa, J.C. Cleveland Jr,
et al., 2019 AHA/ACC/HRS Focused update of the 2014 AHA/ACC/HRS guideline
for the management of patients with atrial fibrillation: a report of the
American College of Cardiology/American Heart Association Task Force on
Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration
With the Society of Thoracic Surgeons, Circulation 140 (2) (2019) e125–e151.
[11] P. Kirchhof, H. Calkins, Catheter ablation in patients with persistent atrial
fibrillation, Eur. Heart J. 38 (1) (2017) 20–26.
[12] J. Heijman, S. Ghezelbash, D. Dobrev, Investigational antiarrhythmic agents:
promising drugs in early clinical development, Expert Opin. Invest. Drugs 26
(8) (2017) 897–907.
[13] S.R. Steinhubl, J. Waalen, A.M. Edwards, L.M. Ariniello, R.R. Mehta, G.S. Ebner,
et al., Effect of a home-based wearable continuous ECG monitoring patch on
detection of undiagnosed atrial fibrillation: the mSToPS randomized clinical
trial, JAMA 320 (2) (2018) 146–155.
[14] A.J. Camm, The role of continuous monitoring in atrial fibrillation
management, Arrhythmia Electrophysiol. Rev. 3 (1) (2014) 48–50.
[15] L.Y. Chen, M.K. Chung, L.A. Allen, M. Ezekowitz, K.L. Furie, P. McCabe, et al.,
Atrial fibrillation burden: moving beyond atrial fibrillation as a binary entity: a
scientific statement from the American Heart Association, Circulation 137 (20)
(2018) e623–e644.
[16] M. Vamos, S.H. Hohnloser, Amiodarone and dronedarone: An update, Trends
Cardiovasc. Med. 26 (7) (2016) 597–602.[17] G. Boriani, C. Blomstrom-Lundqvist, S.H. Hohnloser, L. Bergfeldt, G.L. Botto, A.
Capucci, et al., Safety and efficacy of dronedarone from clinical trials to real-
world evidence: implications for its use in atrial fibrillation, Europace (2019).
[18] L. Valembois, E. Audureau, A. Takeda, W. Jarzebowski, J. Belmin, C. Lafuente-
Lafuente, Antiarrhythmics for maintaining sinus rhythm after cardioversion of
atrial fibrillation, Cochrane Database Syst. Rev. 9 (2019) CD005049.
[19] J. Heijman, J.B. Guichard, D. Dobrev, S. Nattel, Translational challenges in atrial
fibrillation, Circ. Res. 122 (5) (2018) 752–773.
[20] N.C. Denham, C.M. Pearman, J.L. Caldwell, G.W.P. Madders, D.A. Eisner, A.W.
Trafford, et al., Calcium in the pathophysiology of atrial fibrillation and heart
failure, Front. Physiol. 9 (2018) 1380.
[21] C.E. Molina, I.H. Abu-Taha, Q. Wang, E. Rosello-Diez, M. Kamler, S. Nattel, et al.,
Profibrotic, electrical, and calcium-handling remodeling of the atria in heart
failure patients with and without atrial fibrillation, Front. Physiol. 9 (2018)
1383.
[22] X. Li, X. Yang, Y. Li, M. Yuan, C. Tian, Y. Yang, et al., Mitochondria and the
pathophysiological mechanism of atrial fibrillation, Curr. Pharm. Des. 24 (26)
(2018) 3055–3061.
[23] C. Wolke, A. Bukowska, A. Goette, U. Lendeckel, Redox control of cardiac
remodeling in atrial fibrillation, BBA 1850 (8) (2015) 1555–1565.
[24] C. Yao, T. Veleva, L. Scott Jr., S. Cao, L. Li, G. Chen, et al., Enhanced
cardiomyocyte NLRP3 inflammasome signaling promotes atrial fibrillation,
Circulation 138 (20) (2018) 2227–2242.
[25] L. Scott Jr., N. Li, D. Dobrev, Role of inflammatory signaling in atrial fibrillation,
Int. J. Cardiol. 287 (2019) 195–200.
[26] G.A. Dan, D. Dobrev, Antiarrhythmic drugs for atrial fibrillation: Imminent
impulses are emerging, Int. J. Cardiol. Heart Vasculature 21 (2018) 11–15.
[27] W.H. Schunck, A. Konkel, R. Fischer, K.H. Weylandt, Therapeutic potential of
omega-3 fatty acid-derived epoxyeicosanoids in cardiovascular and
inflammatory diseases, Pharmacol. Ther. 183 (2018) 177–204.
[28] C. Arnold, M. Markovic, K. Blossey, G. Wallukat, R. Fischer, R. Dechend, et al.,
Arachidonic acid-metabolizing cytochrome P450 enzymes are targets of
omega-3 fatty acids, J. Biol. Chem. 285 (43) (2010) 32720–131733.
[29] R. Fischer, A. Konkel, H. Mehling, K. Blossey, A. Gapelyuk, N. Wessel, et al.,
Dietary omega-3 fatty acids modulate the eicosanoid profile in man primarily
via the CYP-epoxygenase pathway, J. Lipid Res. 55 (6) (2014) 1150–1164.
[30] V. Samokhvalov, K.L. Jamieson, J. Vriend, S. Quan, J.M. Seubert, CYP-
epoxygenase metabolites of docosahexaenoic acid protect HL-1 cardiac cells
against LPS-induced cytotoxicity Through SIRT1, Cell Death Discov. (2015) 1.
[31] V. Samokhvalov, K.L. Jamieson, I. Fedotov, T. Endo, J.M. Seubert, SIRT is
required for EDP-mediated protective responses toward hypoxia-
reoxygenation injury in cardiac cells, Front. Pharmacol. 7 (2016) 124.
[32] A.M. Darwesh, K.L. Jamieson, C. Wang, V. Samokhvalov, J.M. Seubert,
Cardioprotective effects of CYP-derived epoxy metabolites of
docosahexaenoic acid involve limiting NLRP3 inflammasome activation (1),
Can. J. Physiol. Pharmacol. (2018) 1–13.
[33] C. Westphal, A. Konkel, W.H. Schunck, CYP-eicosanoids–a new link between
omega-3 fatty acids and cardiac disease?, Prostaglandins Other Lipid Mediat.
96 (1–4) (2011) 99–108.
[34] P. Sirish, N. Li, V. Timofeyev, X.D. Zhang, L. Wang, J. Yang, et al., Molecular
mechanisms and new treatment paradigm for atrial fibrillation, Circul.
Arrhythmia Electrophysiol. 9(5) (2016).
[35] C. Westphal, B. Spallek, A. Konkel, L. Marko, F. Qadri, L.M. Degraff, et al., CYP2J2
overexpression protects against arrhythmia susceptibility in cardiac
hypertrophy, PLoS ONE 8 (8) (2013) e73490.
[36] D. Xu, N. Li, Y. He, V. Timofeyev, L. Lu, H.J. Tsai, et al., Prevention and reversal of
cardiac hypertrophy by soluble epoxide hydrolase inhibitors, Proc. Natl. Acad.
Sci. USA 103 (49) (2006) 18733–18738.
[37] A. Lanas, L.A. García-Rodríguez, M.T. Arroyo, et al., Risk of upper
gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2
inhibitors, traditional non-aspirin nonsteroidal anti-inflammatory drugs,
aspirin and combinations, Gut 55 (2006) 1731–1738.
[38] M.L. Hansen, R. Sørensen, M.T. Clausen, et al., Risk of bleeding with single, dual,
or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial
fibrillation, Arch. Intern. Med. 170 (2010) 1433–1441.
[39] R.D. Lopes, M. Rao, D.N. Simon, et al., Triple vs dual antithrombotic therapy in
patients with atrial fibrillation and coronary artery disease, Am. J. Med. 129
(2016) 592–599 e1.
[40] R. Sørensen, M.L. Hansen, S.Z. Abildstrom, et al., Risk of bleeding in patients
with acute myocardial infarction treated with different combinations of
aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective
analysis of nationwide registry data, Lancet 374 (2009) 1967–1974.
[41] G.M. De Ferrari, L.S. Maier, L. Mont, P.J. Schwartz, G. Simonis, M. Leschke, et al.,
Ranolazine in the treatment of atrial fibrillation: results of the dose-ranging
RAFFAELLO (Ranolazine in Atrial Fibrillation Following An ELectricaL
CardiOversion) study, Heart Rhythm 12 (5) (2015) 872–878.
[42] E.I. Charitos, H. Pürerfellner, T.V. Glotzer, P.D. Ziegler, Clinical classifications of
atrial fibrillation poorly reflect its temporal persistence, JACC 63 (25) (2014)
2840–2848.
